Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
cancer
10
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
san francisco blog main
cancer drugs
ipo
new york blog main
san francisco top stories
europe blog main
fda
sanofi
boston
europe top stories
indiana blog main
indiana top stories
new york top stories
novartis
startups
third rock ventures
venture capital
biogen
blueprint medicines
boulder/denver blog main
boulder/denver top stories
deals
deerfield management
detroit blog main
detroit top stories
drug discovery
eli lilly
gilead sciences
investing
melinta therapeutics
national
non-small cell lung cancer
What
medicines
10
×
ipo
cancer
new
drug
research
announced
based
bio
companies
covid
developing
fda
focus
pipeline
proteins
revolution
roundup
targets
therapeutics
years
acquisitions
activity
adding
addition
address
ago
aiming
alltrna
approval
approvals
approves
balance
begin
betting
biogen
biosciences
biotech
bio’s
black
Language
unset
Current search:
biotech
×
cancer
×
medicines
×
@techcrunch.com
2 years ago
Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic